In this pilot cohort, PRS-based risk stratification led to earlier or more intensive screening recommendations in half of the participants, while family history also influenced management.
Abstract
Background Population-based mammographic screening is primarily age-based. However, breast cancer risk is multifactorial, and women may benefit from personalized risk-based screening. This pilot study aimed to explore the use of polygenic risk score (PRS) as a tool for risk stratification in personalized screening. Methods We included 80 women aged 40–49 years referred for clinical mammography. Exclusion criteria were prior breast cancer or premalignant breast disease, and previous genetic testing. After DNA collection, PRS was calculated from 2805 Single Nucleotide Polymorphisms (SNPs). Screening recommendations were based on each participant’s relative 10-year breast cancer risk estimated from PRS and compared with the 10-year risk of an average woman of the same age. Women with a self-reported family history of cancer meeting standard criteria were referred for gene panel testing for pathogenic variants in high-risk genes. A follow up questionnaire regarding participants’ experiences was distributed 6–9 months after PRS testing. Results Mean age was 45.2 years (SD 2.8). Mean relative 10-year breast cancer risk was 1.18 (SD 0.57). Based on PRS, 40 participants were recommended standard biennial screening 50–69 years, while 40 were advised to begin biennial screening before age 50. Among these, 7 were recommended annual mammography from when their 10-year risk reached twice that of an average 50-year-old. Twenty-one women underwent gene panel testing; no pathogenic variants in breast cancer genes were identified. Five women were advised annual mammography from 40–60 years due to family history of breast cancer, regardless of PRS. Most respondents viewed breast cancer risk assessment positively and did not report increased anxiety after testing. Conclusions In this pilot cohort, PRS-based risk stratification led to earlier or more intensive screening recommendations in half of the participants, while family history also influenced management.
This study identified several personal characteristics that were more strongly linked to breast cancer occurrence, highlighting the value of integrating clinical and self-reported information to better understand individual risk and support more targeted prevention and screening efforts.
M. Franchini, F. Denoth, Stefania Pieroni et al.· Cancers· 0 citations
Adherence to national guidelines for genetic testing was high, and the results had a substantial impact on surgical decision-making, and the prevalence of pathogenic variants were identified in 11% of the patients.
Bi-Ying Huang, Anne Kinhult Stålbom, Svetlana Bajalica Lagercrantz et al.· British Journal of Surgery· 0 citations
BCa and inherited genetic susceptibility jointly contribute to increased risk of multiple common diseases, supporting the integration of genetic risk stratification into survivorship care.
Annabelle Ashworth, Zhu-Qing Shi, Huy Tran et al.· JNCI Cancer Spectrum· 0 citations
Variation in IBIS BC-LTR scores over time highlights the need for periodic recalculation to improve individual risk stratification and guide more appropriate, personalised imaging and screening pathways.
M. Keupers, Sam Nijssen, Willem Sarkol et al.· Insights into Imaging· 0 citations
Offering multifactorial BC risk assessments to younger women in primary care, especially the most proactive and broad approaches, would be acceptable and preferred over current practice.
Rebecca A. Dennison, Maria Valasaki, S. Wright et al.· British Journal of Cancer· 0 citations
Utilization of risk-reducing surgery was highest in women with BRCA1/2 PV, and Pancreatic screening was low in all patients, and future studies are needed to examine the factors underlying these trends.
Emily M. Russell, S. Nielsen, R. Ellsworth et al.· JCO Precision Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.